Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) EBITDA: 2023-2024

Historic EBITDA for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to -$15.1 million.

  • Contineum Therapeutics' EBITDA fell 98.82% to -$15.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$42.3 million, marking a year-over-year decrease of 284.66%. This contributed to the annual value of -$42.3 million for FY2024, which is 284.66% down from last year.
  • Latest data reveals that Contineum Therapeutics reported EBITDA of -$15.1 million as of Q4 2024, which was down 57.17% from -$9.6 million recorded in Q3 2024.
  • In the past 5 years, Contineum Therapeutics' EBITDA ranged from a high of $41.5 million in Q2 2023 and a low of -$15.1 million during Q4 2024.
  • In the last 2 years, Contineum Therapeutics' EBITDA had a median value of -$8.1 million in 2023 and averaged -$2.4 million.
  • Data for Contineum Therapeutics' EBITDA shows a maximum YoY crashed of 121.87% (in 2024) over the last 5 years.
  • Over the past 2 years, Contineum Therapeutics' EBITDA (Quarterly) stood at -$7.6 million in 2023, then plummeted by 98.82% to -$15.1 million in 2024.
  • Its last three reported values are -$15.1 million in Q4 2024, -$9.6 million for Q3 2024, and -$9.1 million during Q2 2024.